Pfizer Inc.
PFE
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $162.1B
$28.45
▼ -1.25%
P/E
37.59
Mkt Cap
$162.1B
52-Wk Range
$23.58–$29.21
52-Week Range
$23.58 - $29.21
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Extensive patent portfolio protecting blockbuster drugs with multi-year exclusivity periods
- Global manufacturing and distribution infrastructure enabling rapid market access across 180+ countries
- Strong R&D capabilities and strategic partnerships with leading biotech firms accelerating pipeline innovation
- Diversified product portfolio reducing dependence on single therapeutic areas or drugs
- Established relationships with healthcare providers, governments, and regulatory agencies built over 170+ years
- Scale advantages in clinical trials, regulatory navigation, and commercialization reducing time-to-market
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expanding vaccine portfolio addressing pneumococcal, meningococcal, and emerging infectious diseases
Value
Attractively priced below Large Cap Pharma peer average
Momentum
Strong
+11.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
High yield
6.05% yield
Smart-money signal
Who's buying PFE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $0.77 vs $0.68 consensus (+12.9% surprise). Revenue of $15.0B vs $14.4B expected (+4.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+12.9%
Revenue trend · last 8Q
—
+22%
-8%
+10%
-6%
-1%
+5%
+3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$17.7B
$17.8B
$13.7B
$14.7B
$16.7B
$17.6B
$14.5B
$15.0B
Margins · last 8Q
Gross
72.8%
Operating
31.3%
Profit
-1.6%
Wall Street consensus
8 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
—
Latest: HSBC · Jul 6, 2026
vs Industry
How PFE stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related